BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
T cell receptor signaling pathway
,
HIV infection
,
Kidney
,
Autoimmunity
,
Fenofibrate
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
receptor 1
NextBio Summary
General Info
Curated Studies
Most Correlated Studies
Drug target sets for approved compounds
Human umbilical vein endothelial cells (HUVECs) adhering to soluble VEGFR1 or fibronectin
Drug Matrix In Vivo Toxicogenomic Study - Rat Liver [Codelink]
Broad Connectivity Map (CMAP 2.0) compound database
Drug Matrix In Vivo Toxicogenomic Study - Rat Liver [Affymetrix]
Explore Curated Studies Results
Literature
Most Relevant Literature
Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders.
Allosteric Modulation of the Sigma-1 Receptor Elicits Antipsychotic-like Effects.
Intracellular dynamics of the Sigma-1 receptor observed with super-resolution imaging microscopy.
Effects of Sigma-1 Receptor Ligands on Peripheral Nerve Regeneration.
Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonis…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes
Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy
Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists
A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schiz…
TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ